Bessemer Group’s Novo Nordisk NVO Stock Holding History

Bessemer Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$366K	Sell	7,630 -603	-7%	-$25.9K	﹤0.01%	1255
2026 Q1	$303K	Sell	8,233 -31,787	-79%	-$1.51M	﹤0.01%	1289
2025 Q4	$2.04M	Sell	40,020 -16,913	-30%	-$865K	﹤0.01%	814
2025 Q3	$3.16M	Sell	56,933 -2,053	-3%	-$120K	﹤0.01%	419
2025 Q2	$4.07M	Sell	58,986 -16,772	-22%	-$1.14M	0.01%	382
2025 Q1	$5.26M	Buy	75,758 +5	+0%	+$413	0.01%	347
2024 Q4	$6.52M	Sell	75,753 -1,178	-2%	-$127K	0.01%	369
2024 Q3	$9.16M	Buy	76,931 +3,534	+5%	+$471K	0.02%	324
2024 Q2	$10.5M	Buy	73,397 +53	+0.1%	+$7.02K	0.02%	307
2024 Q1	$9.42M	Sell	73,344 -7,706	-10%	-$917K	0.02%	312
2023 Q4	$8.38M	Buy	81,050 +3,608	+5%	+$357K	0.02%	317
2023 Q3	$7.04M	Buy	77,442 +4,096	+6%	+$361K	0.02%	311
2023 Q2	$5.93M	Sell	73,346 -6,840	-9%	-$559K	0.01%	331
2023 Q1	$6.38M	Sell	80,186 -2,244	-3%	-$159K	0.02%	304
2022 Q4	$5.58M	Buy	82,430 +8,772	+12%	+$514K	0.01%	316
2022 Q3	$3.67M	Buy	73,658 +3,378	+5%	+$181K	0.01%	356
2022 Q2	$3.92M	Buy	70,280 +29,714	+73%	+$1.65M	0.01%	333
2022 Q1	$2.25M	Sell	40,566 -4,426	-10%	-$227K	﹤0.01%	333
2021 Q4	$2.52M	Buy	44,992 +34,358	+323%	+$1.86M	0.01%	312
2021 Q3	$511K	Sell	10,634 -2,648	-20%	-$128K	﹤0.01%	563
2021 Q2	$557K	Buy	13,282 +6,388	+93%	+$248K	﹤0.01%	542
2021 Q1	$232K	Sell	6,894 -56,780	-89%	-$2.02M	﹤0.01%	725
2020 Q4	$2.22M	Buy	63,674 +5,682	+10%	+$196K	0.01%	289
2020 Q3	$2.01M	Sell	57,992 -1,668	-3%	-$55.6K	0.01%	323
2020 Q2	$1.95M	Sell	59,660 -2,278	-4%	-$72.7K	0.01%	493
2020 Q1	$1.86M	Buy	61,938 +3,042	+5%	+$90.6K	0.01%	450
2019 Q4	$1.7M	Buy	58,896 +168	+0.3%	+$4.65K	0.01%	614
2019 Q3	$1.52M	Sell	58,728 -12,018	-17%	-$304K	0.01%	589
2019 Q2	$1.8M	Sell	70,746 -114	-0.2%	-$2.82K	0.01%	567
2019 Q1	$1.85M	Sell	70,860 -5,192	-7%	-$128K	0.01%	480
2018 Q4	$1.75M	Buy	76,052 +1,220	+2%	+$27.1K	0.01%	425
2018 Q3	$1.76M	Sell	74,832 -806	-1%	-$19.7K	0.01%	438
2018 Q2	$1.74M	Sell	75,638 -1,910	-2%	-$45.4K	0.01%	432
2018 Q1	$1.91M	Buy	77,548 +9,028	+13%	+$237K	0.01%	422
2017 Q4	$1.84M	Sell	68,520 -5,456	-7%	-$139K	0.01%	437
2017 Q3	$1.78M	Buy	73,976 +7,200	+11%	+$163K	0.01%	473
2017 Q2	$1.43M	Buy	66,776 +494	+0.7%	+$9.97K	0.01%	561
2017 Q1	$1.14M	Sell	66,282 -1,914	-3%	-$33.3K	﹤0.01%	663
2016 Q4	$1.22M	Sell	68,196 -4,374	-6%	-$79.3K	0.01%	654
2016 Q3	$1.51M	Buy	72,570 +774	+1%	+$19.2K	0.01%	519
2016 Q2	$1.93M	Buy	71,796 +1,572	+2%	+$43.1K	0.01%	393
2016 Q1	$1.9M	Buy	70,224 +576	+0.8%	+$15.4K	0.01%	393
2015 Q4	$2.02M	Buy	69,648 +9,278	+15%	+$257K	0.01%	431
2015 Q3	$1.64M	Sell	60,370 -9,000	-13%	-$255K	0.01%	461
2015 Q2	$1.9M	Buy	69,370 +12,872	+23%	+$362K	0.01%	430
2015 Q1	$1.51M	Sell	56,498 -3,442	-6%	-$79.3K	0.01%	460
2014 Q4	$1.27M	Buy	59,940 +1,502	+3%	+$33.5K	0.01%	444
2014 Q3	$1.39M	Buy	58,438 +1,058	+2%	+$24.3K	0.01%	420
2014 Q2	$1.32M	Sell	57,380 -390	-0.7%	-$8.61K	0.01%	410
2014 Q1	$1.32M	Sell	57,770 -22,650	-28%	-$483K	0.01%	393
2013 Q4	$1.49M	Buy	80,420 +21,070	+36%	+$367K	0.01%	387
2013 Q3	$1M	Sell	59,350 -20,000	-25%	-$336K	0.01%	412
2013 Q2	$1.23M	Buy	+79,350	New	+$1.32M	0.01%	372

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bessemer Group's NVO Position: Q2 2026 in Review

Bessemer Group reduced its Novo Nordisk (NVO) stake by 7.3% in Q2 2026, selling an estimated $25.9K and leaving 7,630 shares worth $366K. The position accounts for ﹤0.01% of the portfolio, ranked #1255.

Bessemer Group first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $10.5M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Bessemer Group held 7,630 shares of Novo Nordisk worth $366K as of Q2 2026.
Bessemer Group sold 603 Novo Nordisk shares in Q2 2026, an estimated $25.9K.
Novo Nordisk made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1255 holding.
Bessemer Group first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
Bessemer Group's Novo Nordisk position peaked at $10.5M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.